---
title: "Long-term fatigue dimensions after radiotherapy in non-metastatic prostate cancer: MFI trajectorie"
id: "british-journal-of-cancer-1-long-term-fatigue-dimensions-in-the-multidimensional-fatigue-inventory-mfi-up"
canonical_url: "https://medichelpline.com/clinical-feed/british-journal-of-cancer-1-long-term-fatigue-dimensions-in-the-multidimensional-fatigue-inventory-mfi-up"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "British Journal of Cancer"
source_url: "https://www.nature.com/articles/s41416-026-03626-4"
published_at: "2026-11-09T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Long-term fatigue dimensions after radiotherapy in non-metastatic prostate cancer: MFI trajectorie
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/british-journal-of-cancer-1-long-term-fatigue-dimensions-in-the-multidimensional-fatigue-inventory-mfi-up
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** British Journal of Cancer
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41416-026-03626-4)
- **Published At:** 2026-11-09T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Cohort size: 1,097 men with non-metastatic **prostate cancer** treated with **radiotherapy** between 2014 and 2016, prospectively followed with the **Multidimensional Fatigue Inventory (MFI)** up to five years. - Prevalent fatigue was defined using the 75th percentile of men aged ≥60 from a German general population reference; the same threshold applied across the five MFI dimensions. - Overall, 72% (785/1,097) of patients reported fatigue in at least one MFI dimension from baseline through five years; 45% (367/816) were fatigued at two years post-radiotherapy. - Investigators used logistic regression to examine associations between pre-radiotherapy characteristics and each MFI dimension two years later (general fatigue, physical fatigue, mental fatigue, reduced activity, reduced motivation). - Pre-radiotherapy fatigue level was a strong predictor of long-term fatigue (reported OR range: 4.7–9.0 across dimensions). - Depression (OR ~2.5), diabetes (OR range: 1.8–2.2), hypertension (OR range: 1.6–1.8), and higher BMI (OR range: 1.8–2.2) were statistically significant predictors for long-term fatigue two years after radiotherapy. - Latent class growth analysis identified distinct fatigue trajectories up to two years; depression, BMI, and pelvic radiotherapy were associated with membership in a high-fatigue trajectory. - Investigators compared multidimensional fatigue up to five years with population reference values and with fatigue data from women with non-metastatic breast cancer within the REQUITE cohort; the source did not provide detailed comparative statistics in the abstract. - Authors noted that early fatigue assessment plus comorbidity and BMI information provided prognostic value beyond symptom detection and could inform targeted symptom management; the source did not report specific intervention strategies or dosing. - The study aimed to identify pre-radiotherapy demographic, disease-, and treatment-specific characteristics associated with fatigue dimensions and trajectories; prior literature on prostate cancer fatigue had been limited by small samples and short follow-up.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41416-026-03626-4#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![British Journal of Cancer](https://media.springernature.com/full/nature-cms/uploads/product/bjc/header-76ac17391903a21e28f15ff5df31f5fa.svg) ](https://www.nature.com/bjc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41416-026-03626-4) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/bjc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/bjc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/bjc/news-and-comment) * [ Current issue ](https://www.nature.com/bjc/current-issue) * [ Collections ](https://www.nature.com/bjc/collections) * [Follow us on X ](https://twitter.com/BrJCancer) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Journal Information ](https://www.nature.com/bjc/journal-information) * [ Open access publishing ](https://www.nature.com/bjc/open-access) * [ Editors ](https://www.nature.com/bjc/editors) * [ Contact ](https://www.nature.com/bjc/contact) * [ Special Issues ](https://www.nature.com/bjc/special-issues) * [ For Advertisers ](https://www.nature.com/bjc/advertising) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors & Referees ](https://www.nature.com/bjc/authors-and-referees) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/bjc/open-access-funding) * [Submit manuscript ](https://mts-bjcancer.nature.com/) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) 1. [nature](https://www.nature.com/) 2. [british journal of cancer](https://www.nature.com/bjc) 3. [articles](https://www.nature.com/bjc/articles?type=article) 4. article Long-term fatigue dimensions in the Multidimensional Fatigue Inventory (MFI) up to five years after radiotherapy and their trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study [ Download PDF ](https://www.nature.com/articles/s41416-026-03626-4.pdf) [ Download PDF ](https://www.nature.com/articles/s41416-026-03626-4.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 09 November 2026 Epidemiology # Long-term fatigue dimensions in the Multidimensional Fatigue Inventory (MFI) up to five years after radiotherapy and their trajectories in men diagnosed with non-metastatic prostate cancer in the international REQUITE study * [Philipp Heumann](https://www.nature.com/articles/s41416-026-03626-4#auth-Philipp-Heumann-Aff1-Aff2)[1](https://www.nature.com/articles/s41416-026-03626-4#Aff1),[2](https://www.nature.com/articles/s41416-026-03626-4#Aff2), * [Juan C. Rosas](https://www.nature.com/articles/s41416-026-03626-4#auth-Juan_C_-Rosas-Aff1)[1](https://www.nature.com/articles/s41416-026-03626-4#Aff1), * [Miguel E. Aguado-Barrera](https://www.nature.com/articles/s41416-026-03626-4#auth-Miguel_E_-Aguado_Barrera-Aff3-Aff4) [ORCID: orcid.org/0000-0002-7822-6726](https://orcid.org/0000-0002-7822-6726)[3](https://www.nature.com/articles/s41416-026-03626-4#Aff3),[4](https://www.nature.com/articles/s41416-026-03626-4#Aff4), * [David Azria](https://www.nature.com/articles/s41416-026-03626-4#auth-David-Azria-Aff5)[5](https://www.nature.com/articles/s41416-026-03626-4#Aff5), * [Axel Benner](https://www.nature.com/articles/s41416-026-03626-4#auth-Axel-Benner-Aff6)[6](https://www.nature.com/articles/s41416-026-03626-4#Aff6), * [Erik Briers](https://www.nature.com/articles/s41416-026-03626-4#auth-Erik-Briers) [na1](https://www.nature.com/articles/s41416-026-03626-4#na1), * [Renée Bultijnck](https://www.nature.com/articles/s41416-026-03626-4#auth-Ren_e-Bultijnck-Aff7-Aff8) [ORCID: orcid.org/0000-0003-4122-2323](https://orcid.org/0000-0003-4122-2323)[7](https://www.nature.com/articles/s41416-026-03626-4#Aff7),[8](https://www.nature.com/articles/s41416-026-03626-4#Aff8), * [Ananya Choudhury](https://www.nature.com/articles/s41416-026-03626-4#auth-Ananya-Choudhury-Aff9)[9](https://www.nature.com/articles/s41416-026-03626-4#Aff9), * [Antonio Gómez-Caamaño](https://www.nature.com/articles/s41416-026-03626-4#auth-Antonio-G_mez_Caama_o-Aff4-Aff10) [ORCID: orcid.org/0000-0002-9773-4590](https://orcid.org/0000-0002-9773-4590)[4](https://www.nature.com/articles/s41416-026-03626-4#Aff4),[10](https://www.nature.com/articles/s41416-026-03626-4#Aff10), * [Rudolf Kaaks](https://www.nature.com/articles/s41416-026-03626-4#auth-Rudolf-Kaaks-Aff1) [ORCID: orcid.org/0000-0003-3751-3929](https://orcid.org/0000-0003-3751-3929)[1](https://www.nature.com/articles/s41416-026-03626-4#Aff1), * [Maarten Lambrecht](https://www.nature.com/articles/s41416-026-03626-4#auth-Maarten-Lambrecht-Aff11) [ORCID: orcid.org/0000-0002-8746-2691](https://orcid.org/0000-0002-8746-2691)[11](https://www.nature.com/articles/s41416-026-03626-4#Aff11), * [Tiziana Rancati](https://www.nature.com/articles/s41416-026-03626-4#auth-Tiziana-Rancati-Aff12) [ORCID: orcid.org/0000-0002-7849-603X](https://orcid.org/0000-0002-7849-603X)[12](https://www.nature.com/articles/s41416-026-03626-4#Aff12), * [Barry S. Rosenstein](https://www.nature.com/articles/s41416-026-03626-4#auth-Barry_S_-Rosenstein-Aff13)[13](https://www.nature.com/articles/s41416-026-03626-4#Aff13), * [Dirk De Ruysscher](https://www.nature.com/articles/s41416-026-03626-4#auth-Dirk-De_Ruysscher-Aff14)[14](https://www.nature.com/articles/s41416-026-03626-4#Aff14), * [Martina E. Schmidt](https://www.nature.com/articles/s41416-026-03626-4#auth-Martina_E_-Schmidt-Aff15) [ORCID: orcid.org/0000-0002-2095-2426](https://orcid.org/0000-0002-2095-2426)[15](https://www.nature.com/articles/s41416-026-03626-4#Aff15), * [Susanne Singer](https://www.nature.com/articles/s41416-026-03626-4#auth-Susanne-Singer-Aff16)[16](https://www.nature.com/articles/s41416-026-03626-4#Aff16), * [Elena Sperk](https://www.nature.com/articles/s41416-026-03626-4#auth-Elena-Sperk-Aff17) [ORCID: orcid.org/0000-0002-8771-8124](https://orcid.org/0000-0002-8771-8124)[17](https://www.nature.com/articles/s41416-026-03626-4#Aff17), * [Hilary Stobart](https://www.nature.com/articles/s41416-026-03626-4#auth-Hilary-Stobart) [na1](https://www.nature.com/articles/s41416-026-03626-4#na1), * [Ana Vega](https://www.nature.com/articles/s41416-026-03626-4#auth-Ana-Vega-Aff3-Aff4-Aff18) [ORCID: orcid.org/0000-0002-7416-5137](https://orcid.org/0000-0002-7416-5137)[3](https://www.nature.com/articles/s41416-026-03626-4#Aff3),[4](https://www.nature.com/articles/s41416-026-03626-4#Aff4),[18](https://www.nature.com/articles/s41416-026-03626-4#Aff18), * [Liv Veldeman](https://www.nature.com/articles/s41416-026-03626-4#auth-Liv-Veldeman-Aff7-Aff8)[7](https://www.nature.com/articles/s41416-026-03626-4#Aff7),[8](https://www.nature.com/articles/s41416-026-03626-4#Aff8), * [Tim Ward](https://www.nature.com/articles/s41416-026-03626-4#auth-Tim-Ward) [na1](https://www.nature.com/articles/s41416-026-03626-4#na1), * [Adam Webb](https://www.nature.com/articles/s41416-026-03626-4#auth-Adam-Webb-Aff19) [ORCID: orcid.org/0000-0002-6699-0479](https://orcid.org/0000-0002-6699-0479)[19](https://www.nature.com/articles/s41416-026-03626-4#Aff19), * [Catharine M. West](https://www.nature.com/articles/s41416-026-03626-4#auth-Catharine_M_-West-Aff20) [ORCID: orcid.org/0000-0002-0839-3449](https://orcid.org/0000-0002-0839-3449)[20](https://www.nature.com/articles/s41416-026-03626-4#Aff20), * [Jenny Chang-Claude](https://www.nature.com/articles/s41416-026-03626-4#auth-Jenny-Chang_Claude-Aff1)[1](https://www.nature.com/articles/s41416-026-03626-4#Aff1), * [Christopher J. Talbot](https://www.nature.com/articles/s41416-026-03626-4#auth-Christopher_J_-Talbot-Aff19) [ORCID: orcid.org/0000-0001-7406-8962](https://orcid.org/0000-0001-7406-8962)[19](https://www.nature.com/articles/s41416-026-03626-4#Aff19), * [Tim Rattay](https://www.nature.com/articles/s41416-026-03626-4#auth-Tim-Rattay-Aff19)[19](https://www.nature.com/articles/s41416-026-03626-4#Aff19), * [REQUITE/REQUITEplus/RADprecise consortia](https://www.nature.com/articles/s41416-026-03626-4#group-1) & * … * [Petra Seibold](https://www.nature.com/articles/s41416-026-03626-4#auth-Petra-Seibold-Aff1-Aff21) [ORCID: orcid.org/0000-0001-7360-6335](https://orcid.org/0000-0001-7360-6335)[1](https://www.nature.com/articles/s41416-026-03626-4#Aff1),[21](https://www.nature.com/articles/s41416-026-03626-4#Aff21) Show authors [_British Journal of Cancer_](https://www.nature.com/bjc) (2026) [Cite this article](https://www.nature.com/articles/s41416-026-03626-4#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract ### Background Fatigue is a common, multidimensional symptom in cancer patients. Little is known about fatigue dimensions and their trajectories in prostate cancer (PCa). ### Methods Using the Multidimensional Fatigue Inventory (MFI), 1097 men treated with radiotherapy for non-metastatic PCa (2014–2016) prospectively reported fatigue up to five years later. Prevalent fatigue was defined as scores ≥75th percentile in men aged ≥60 years in a German general population sample. Pre-radiotherapy patient characteristics were examined for their associations with general fatigue, physical fatigue, mental fatigue, reduced activity, and reduced motivation two years later using logistic regression models. Fatigue trajectories up to two years post-radiotherapy were explored using latent class growth analysis and multinomial regression. ### Results About 72% (785/1097) of patients reported being fatigued for at least one dimension in the MFI from before the start of radiotherapy up to five years later, with 45% (367/816) being fatigued two years post-radiotherapy. Pre-radiotherapy fatigue level (OR: 4.7–9.0), depression (OR: 2.5), diabetes (OR: 1.8–2.2), hypertension (OR: 1.6–1.8), and BMI (OR: 1.8–2.2) were statistically significant predictors of long-term fatigue two years post-radiotherapy across dimensions. Depression, BMI, and pelvic radiotherapy were associated with experiencing a high fatigue trajectory. ### Conclusions Early fatigue assessments, in addition to self-reported comorbidities and BMI, showed additional benefits beyond symptom detection by providing prognostic value for poorer long-term fatigue outcomes. Multidimensional fatigue assessments could guide tailored symptom management strategies, targeting specific dimensions to address associated impairments in quality of life and functioning. ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer epidemiology](https://www.nature.com/subjects/cancer-epidemiology) * [Prostate cancer](https://www.nature.com/subjects/prostate-cancer) ## Background Fatigue is a complex symptom with multiple clinical manifestations, which is associated with impairments in functioning and quality of life (QoL) [[1](https://www.nature.com/articles/s41416-026-03626-4#ref-CR1 "Horneber M, Fischer I, Dimeo F, Rüffer JU, Weis J. Cancer-related fatigue. Epidemiology, Pathogenesis, Diagnosis, and Treatment. Dtsch Arztebl Int. 2012;109:161–71. https://doi.org/10.3238/arztebl.2012.0161 ."), [2](https://www.nature.com/articles/s41416-026-03626-4#ref-CR2 "Charalambous A, Giannakopoulou M, Bozas E, Paikousis L. Parallel and serial mediation analysis between pain, anxiety, depression, fatigue and nausea, vomiting and retching within a randomised controlled trial in patients with breast and prostate cancer. BMJ Open. 2019;9:e026809 https://doi.org/10.1136/bmjopen-2018-026809 .")]. Most cancer patients experience fatigue during radiotherapy, chemotherapy, bone marrow transplantation, or treatment with immunomodulators, while a substantial proportion of cancer survivors report feeling fatigued even years after treatment completion [[3](https://www.nature.com/articles/s41416-026-03626-4#ref-CR3 "Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, et al. National Comprehensive Cancer Network. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015;13:1012–39. https://doi.org/10.6004/jnccn.2015.0122 ."), [4](https://www.nature.com/articles/s41416-026-03626-4#ref-CR4 "Gavin AT, Drummond FJ, Donnelly C, O’Leary E, Sharp L, Kinnear HR. Patient-reported ‘ever had’ and ‘current’ long-term physical symptoms after prostate cancer treatments. BJU Int. 2015;116:397–406. https://doi.org/10.1111/bju.13036 .")]. Symptom assessment is usually based on patient self-reports using questionnaires [[5](https://www.nature.com/articles/s41416-026-03626-4#ref-CR5 "Stone PC, Minton O. Cancer-related fatigue. Eur J Cancer. 2008;44:1097–104. https://doi.org/10.1016/j.ejca.2008.02.037 .")]. While unidimensional measures are limited to capturing fatigue severity and intensity, multidimensional assessments provide a broader perspective on the symptom experience across distinct fatigue dimensions affecting patients’ behavioural, cognitive, somatic, and affective domains of functioning [[6](https://www.nature.com/articles/s41416-026-03626-4#ref-CR6 "NCCN. Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue Version 2.2025. https://www.nccn.org/ . Accessed April 8, 2025."),[7](https://www.nature.com/articles/s41416-026-03626-4#ref-CR7 "Amarsheda S, Bhise AR. Systematic review of cancer-related fatigue instruments in breast cancer patients. Palliat Support Care. 2022;20:122–8. https://doi.org/10.1017/S1478951521000444 ."),[8](https://www.nature.com/articles/s41416-026-03626-4#ref-CR8 "Jean-Pierre P, Figueroa-Moseley CD, Kohli S, Fiscella K, Palesh OG, Morrow GR. Assessment of cancer-related fatigue: implications for clinical diagnosis and treatment. Oncologist. 2007;12:11–21. https://doi.org/10.1634/theoncologist.12-S1-11 ."),[9](https://www.nature.com/articles/s41416-026-03626-4#ref-CR9 "Whitehead L. The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures. J Pain Symptom Manag. 2009;37:107–28. https://doi.org/10.1016/j.jpainsymman.2007.08.019 .")]. Although prostate cancer is the second most common cancer in men, with up to 82% of patients experiencing fatigue, little is known about fatigue dimensions and their trajectories in prostate cancer patients and survivors, as previous studies have mostly been limited by small sample sizes and short follow-up time [[10](https://www.nature.com/articles/s41416-026-03626-4#ref-CR10 "Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63. https://doi.org/10.3322/caac.21834 ."),[11](https://www.nature.com/articles/s41416-026-03626-4#ref-CR11 "Cornford P, Robijn E, Rogers E, Wassersug R, Fleure L. Fatigue in prostate cancer: a roundtable discussion and thematic literature review. Eur Urol Open Sci. 2024;63:119–25. https://doi.org/10.1016/j.euros.2024.03.003 ."),[12](https://www.nature.com/articles/s41416-026-03626-4#ref-CR12 "Dickinson K, Kupzyk K, Saligan L. Evaluating dimensions of fatigue in men with prostate cancer receiving radiation therapy. Cancer Nurs. 2021;44:71–78. https://doi.org/10.1097/NCC.0000000000000782 ."),[13](https://www.nature.com/articles/s41416-026-03626-4#ref-CR13 "Choo R, Pearce A, Danjoux C, Morton G, Deboer G, Szumacher E, et al. Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy. Eur Urol. 2007;52:1645–50. https://doi.org/10.1016/j.eururo.2006.11.018 ."),[14](https://www.nature.com/articles/s41416-026-03626-4#ref-CR14 "Geinitz H, Thamm R, Scholz C, Heinrich C, Prause N, Kerndl S, et al. Longitudinal analysis of quality of life in patients receiving conformal radiation therapy for prostate cancer. Strahlenther Onkol. 2010;186:46–52. https://doi.org/10.1007/s00066-009-2023-7 .")]. Identifying pre-radiotherapy characteristics associated with specific fatigue dimensions could inform tailored early detection of patients susceptible to poorer long-term fatigue outcomes and facilitate targeted symptom management. The aim of this analysis was to identify demographic, disease-, and treatment-specific characteristics prior to radiotherapy associated with long-term fatigue dimensions and their trajectories up to two years later in men diagnosed with non-metastatic prostate cancer. In addition, multidimensional fatigue assessments of prostate cancer patients using the Multidimensional Fatigue Inventory (MFI) questionnaire up to five years following radiotherapy were compared with (i) population-based reference values, (ii) fatigue assessments of women diagnosed with non-metastatic breast cancer in the REQUITE cohort, and (iii) fatigue assessments usin
## Related Clinical Research

- [New Multi-Society Framework Defines Female Life Stages for Heart Health](https://medichelpline.com/clinical-feed/aha-news-2-leading-health-groups-redefine-heart-health-for-girls-and-women.md)
- [Diet and Alzheimer’s risk: Why no single best diet fits everyone](https://medichelpline.com/clinical-feed/medical-news-today-0-is-there-a-best-diet-to-help-lower-alzheimer-s-risk.md)
- [Avoiding smoking, diabetes, and high blood pressure in midlife may add up to 13 dementia-free years](https://medichelpline.com/clinical-feed/medical-news-today-0-avoiding-3-risk-factors-in-midlife-could-add-13-dementia-free-years.md)
- [Long-term fatigue after radiotherapy in non-metastatic prostate cancer: five-year REQUITE QLQ-C30](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-long-term-fatigue-based-on-the-eortc-qlq-c30-up-to-five-years-after.md)
- [Healthy lifestyle and pan-cancer risk: UK Biobank prospective analysis](https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-healthy-lifestyle-and-cancer-risk-a-pan-cancer-analysis-in-the-uk-biobank.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.